GlassScriptPhysician profile
Brandon Frederick Bodie
NPI 1912401258
$6,872.26
in general payments reported to CMS, 2019-2025
39 companies · $725 in 2025
The $725 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $46.42 · 2022: $2,174 · 2023: $2,113 · 2024: $1,814 · 2025: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,643 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,642.74 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,126.65 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,023.33 | 2022-2025 | Vraylar, Linzess, Viberzi |
| Janssen Pharmaceuticals, INC | $677.05 | 2022-2025 | Spravato, Xarelto |
| Astrazeneca Pharmaceuticals LP | $634.26 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $388.44 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $302.37 | 2022-2024 | |
| Shield Therapeutics INC | $300.94 | 2023-2025 | Accrufer |
| Glaxosmithkline, LLC. | $296.51 | 2022-2025 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $205.78 | 2023-2025 | |
| Amgen INC. | $194.31 | 2022-2024 | Otezla, Repatha, Enbrel |
| Phathom Pharmaceuticals, INC. | $178.11 | 2024-2025 | Voquezna |
| Pfizer INC. | $149.77 | 2022-2025 | |
| Nevro Corp. | $138.82 | 2022-2024 | Senza |
| Idorsia Pharmaceuticals US INC | $121.92 | 2022-2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $111.49 | 2021-2024 | Trintellix |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Bodie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.